
NUVISAN



Harness the Power of Lipid Nanoparticles (LNPs) for Next-Gen Therapeutics!

Discover the potential of nucleic acid therapeutics with our cuttingedge LNP platform. Collaborate with us to benefit from advanced RNA delivery technologies and extensive expertise.

Our comprehensive suite of **analytical tools** offers insights into:

- · In vitro delivery mechanisms
- · In vivo biodistribution patterns
- · Tissue targeting efficacy
- · Immune response dynamics and tolerability

Our Key Services:

- Bioluminescence in vivo imaging for real-time monitoring of RNA delivery
- Detection and visualization techniques including single-cell barcode sequencing, RNAscope™, qPCR, and immunohistochemistry (IHC)

Ensure Safety:

 Assess the tolerability of novel LNPs with ex vivo cytokine profiling, liver enzyme profiling, and complement activation assessment. Choose from safety packages or single toxicology studies tailored to your needs!

Contact us

NUVISAN



Explore Our LNP Delivery Platform!

Advanced In Vitro Delivery Analysis:

Unlock the potential of your lipid nanoparticle (LNP) formulations with our high-content analysis, offering detailed insights into cellular LNP entry, endosomal escape, and RNA translation. Our multiplexed assays enable simultaneous measurement of three critical cellular steps:

LNP Uptake:

Quantification of Cy5-labelled RNA delivered by LNPs

Endosomal Escape:

Utilization of fluorescent Gal9 reporter for precise assessment
 Delivery:

- · Evaluation of GFP expression from delivered RNA
- Versatile assay system adaptable to various cell lines, including those from different tissues or iPSCs

In Vivo Biodistribution Assessment:

- Bioluminescence in vivo imaging of LNP:luc mRNA (BLI)
- · Ex vivo analyses
- · Single-cell sequencing
- · hEPO (ELISA)
- RNA in situ hybridization (RNAscope™)
- Target mRNA quantification (qPCR), and IHC

Tolerability Assessment:

Ensure safety and tolerability with our comprehensive studies via:

- · Cytokine profiling
- · Liver enzyme profiling
- · Complement activation

Tailored safety packages or single toxicology studies. Available in both non-GLP and GLP formats.

Contact us

NUVISAN ICB GmbH Muellerstr. 178 13353 Berlin, German Web: www.nuvisan.com
Email: hello@nuvisan.con
LinkedIn: company/nuvisan